Geode Capital Management LLC Acquires 12,783 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Geode Capital Management LLC raised its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 1.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 768,740 shares of the company’s stock after purchasing an additional 12,783 shares during the period. Geode Capital Management LLC owned 1.46% of Kodiak Sciences worth $2,007,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. GSA Capital Partners LLP purchased a new position in Kodiak Sciences during the 3rd quarter valued at about $751,000. Acadian Asset Management LLC lifted its holdings in shares of Kodiak Sciences by 14.1% during the second quarter. Acadian Asset Management LLC now owns 1,965,449 shares of the company’s stock valued at $4,614,000 after purchasing an additional 242,559 shares during the last quarter. FMR LLC boosted its position in shares of Kodiak Sciences by 26.4% in the 3rd quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after purchasing an additional 41,987 shares in the last quarter. State Street Corp boosted its position in shares of Kodiak Sciences by 1.8% in the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock worth $2,131,000 after purchasing an additional 14,711 shares in the last quarter. Finally, Sei Investments Co. grew its stake in shares of Kodiak Sciences by 27.1% in the 2nd quarter. Sei Investments Co. now owns 143,841 shares of the company’s stock worth $338,000 after buying an additional 30,683 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Barclays upped their target price on shares of Kodiak Sciences from $3.00 to $4.00 and gave the stock an “underweight” rating in a research note on Friday, November 15th. Jefferies Financial Group upgraded Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Monday, December 9th. Finally, HC Wainwright restated a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a research note on Friday, November 15th.

Kodiak Sciences Trading Down 3.9 %

Shares of NASDAQ KOD opened at $9.20 on Thursday. Kodiak Sciences Inc. has a 12-month low of $2.18 and a 12-month high of $11.60. The firm’s 50-day moving average price is $7.42 and its 200-day moving average price is $4.39. The stock has a market capitalization of $484.14 million, a price-to-earnings ratio of -2.52 and a beta of 2.11.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.